Liftoff Houston took place for the 11th year this past weekend. Here's who won prizes. Photo courtesy of the city of Houston

An annual pitch competition put on by the city of Houston named its big winners for this year.

The 11th annual Liftoff Houston Startup Business Plan Competition announced its three winners — and each will receive $10,000 in startup money. The winners are:

  • Teria Johnson's e-commerce sweet and savory pies company, Charleston Kitchen
  • Zoey Barker and Mohammadmehdi Mortazavi’s ExoBraced’s ExoBak, a light-weight exoskeleton to help with back pain and prevent injuries from manual workers
  • Giovanni Garza’s Classic Borrego Retail, which offers high-end cowboy boots.

There were nine finalists that were selected from over 100 applicants and competed in Liftoff’s Pitch Day on November 18, where they were ranked on service, product, and innovation after pitching their businesses to a panel of expert judges.

In the event’s 11 years, 33 winners started businesses in the fields of merchandise/retail, software,education, hardware, hospitality, health and wellness, finance, technology,consulting, and logistics. The yearly event is sponsored by Capital One Bank and administered by the Houston Public Library and the Office of Business Opportunity. Liftoff Houston’s results have reflected the diversity of the city.

“The program is especially significant as data collected from recent competitions shows Liftoff Houston made an impact on populations that have been historically marginalized,” says Mayor Sylvester Turner in a news release. “More than 90 percent of participants identified as people of color, more than 70 percent were female, 44 percent had no college degree, and 54 percent earned less than $50,000 a year.”

Runners received $500 each. They are:

  • Francesca Bonaduc’e De Nigris: Intrecci by Francesca collaborates with artisans around the world, to deliver one-of-a-kind handmade rugs.
  • Diana Tudela and Hailee Trombley’s The Goodest Goodbye: a pet aftercare company that uses cutting-edge technology and environmentally conscious efforts.
  • Diane Nguyen’s Flourishing Nexus LLC: a virtual platform that unites health professionals worldwide.

Liftoff Houston – and our finalists – have also made it this far because of our workshop partners, all who have given us the invaluable gift of their time,” says OBO Director Marsha Murray in a news release. “The business, financial, legal and marketing education they have provided has allowed our participants to plan a roadmap to their success, including the creation of viable business plans.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”